RxDoctor Payments Data

Marleena Dimaggio, APRN

Nurse Practitioner · Fairfield, CTNPI 1194727172

Payments from drug & device makers

$823in general payments, 2019–2025

Across 41 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$577
  • Exact Sciences$86
  • Astellas Pharma US Inc$52
  • Abbott$44
  • Pfizer$30
  • GSK$17
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$823100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk30$577
Exact Sciences4$86
Astellas Pharma US Inc2$52
Abbott2$44
Pfizer1$30
GSK1$17
AstraZeneca1$17

How this compares

$823 in reported general payments places this provider in the 85th percentile of 1,162 nurse practitioner providers in Connecticut.

See all nurse practitioner providers in Connecticut

Medicare billing

Part B allowed, 2024
$5,676
Medicare patients
20
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$48,967
JardianceEmpagliflozin42$44,292
RybelsusSemaglutide22$29,436
Tresiba Flextouch U-200Insulin Degludec39$26,707
LinzessLinaclotide27$23,495
VascepaIcosapent Ethyl22$15,671
TrintellixVortioxetine Hydrobromide17$10,268
SymbicortBudesonide/Formoterol Fumarate12$2,843
Epinephrine11$2,794
Albuterol Sulfate HfaAlbuterol Sulfate80$2,437
Lidocaine14$1,924
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp17$1,856
Nano 2nd Gen Pen NeedlePen Needle, Diabetic16$1,053
Levocetirizine Dihydrochloride52$753
Rosuvastatin Calcium74$711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$577$78,40371 claims
AstraZenecaSymbicort$17$2,84312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,162 nurse practitioner providers in Connecticut.

Other nurse practitioner in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →